Medication info
Rosuvastatin Calcium 5 mg Tablets

Rosuvastatin Calcium 5 mg Tablets

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
NBK Pharmaceuticals Co., Ltd.
Appearance
Yellow round film-coated tablets
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201906579 · Approved 2019.09.19 · Insurance code 054800390

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease
Who uses it
Adults
Adult dosage
1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately according to LDL cholesterol levels, treatment goals, and patient response at intervals of 4 weeks or longer, and may be increased up to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Ingredients

Manufacturer
NBK Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease

  • Hypercholesterolemia
  • mixed hyperlipidemia
  • familial hypercholesterolemia
  • dysbetalipoproteinemia
  • risk factors for coronary heart disease
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease.
View approved original text

This drug is used as an adjunct for patients with primary hypercholesterolemia and mixed hyperlipidemia when diet and exercise alone are not sufficient. It is also used in conjunction with diet or other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. In patients with hypercholesterolemia, it helps lower total cholesterol and LDL cholesterol levels, thereby slowing the progression of atherosclerosis. It is also used as an adjunct to the diet for patients with primary dysbetalipoproteinemia. Additionally, it contributes to reducing the risk of myocardial infarction, stroke, and complications following arterial revascularization in men over the age of 50 and women over the age of 60 with elevated high-sensitivity C-reactive protein levels and other cardiovascular disease risk factors. This drug effectively improves dyslipidemia and cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately according to LDL cholesterol levels, treatment goals, and patient response at intervals of 4 weeks or longer, and may be increased up to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Precautions

This drug should not be administered to certain patients. First, it should not be taken by individuals who are allergic to any component of this medication. It should also not be used in cases of active liver disease or when liver enzyme levels are abnormally high. Patients with muscle disorders or severe renal impairment should avoid this medication. Women who are pregnant or breastfeeding, as well as women of childbearing potential without appropriate contraception, should not take this drug. Additionally, high doses are especially prohibited for patients at risk of myopathy or rhabdomyolysis. This drug contains lactose, so patients with lactose intolerance or related genetic disorders should not take it. Patients taking this medication should have their liver function and muscle condition monitored regularly. Particular caution is needed for patients who consume significant amounts of alcohol or have a history of liver disease. If muscle pain or weakness symptoms arise, notify healthcare providers immediately, and in severe cases, discontinue the medication. In acute illness or severe conditions, it is advisable to stop taking this medication. Moreover, this drug can interact with other medications, so be sure to inform the prescribing physician of any other medications being taken. In particular, using it alongside fibric acid derivatives may increase the risk of muscle-related side effects. Pregnant or breastfeeding women should not use this drug, and women of childbearing potential must ensure contraception. In case of overdose, there are no specific antidotes, so treatment should be symptomatic and include liver and muscle testing. This drug is known not to significantly affect driving or machine operation; however, be cautious of symptoms such as dizziness. Finally, this drug may show higher blood concentration levels in Asians, so dosage adjustments may be necessary.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, discomfort in the chest, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

Store this drug in a tightly closed container to protect it from air and moisture. It is recommended to keep the storage temperature between 1 to 30 degrees Celsius in a cool area.

Appearance and packaging

Appearance

Yellow round film-coated tablets

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.